参考文献/References:
[1] Edward GS, Meihua W, Stephen WC, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, andvincristine chemotherapy for supratentorial adult low-gradeglioma: initial results of RTOG 9802 [J]. J Clin Oncol,2012, 30(25): 3065-3070.
[2] Yung WK, Prados MD, Yaya TR, et al. Multicenter phaseⅡ trial of temozolomide in patients with anaplastic astro-cytoma or anaplastic oligoastrocytoma at first relapse:Temodal Brain Tumor Group [J]. J Clin Oncol, 1999, 17(9):2762-2771.
[3] Spiegel BM, Esrailian E, Laine L, et al. Clinical impact ofadjuvant chemotherapy in glioblastoma multiforme: a metaanalysis [J]. CNS Drugs, 2007, 21(9): 775-787.
[4]白洁，晨，何灵，等.高级别胶质瘤临床诊疗进展 [J].医述， 2017，23（15）：2978-2982.
[5] Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticityand heterogeneity in cancer [J]. Clin Chem, 2013, 59: 168-179.
[6] Couturier CP, Ayyadhury S, Le PU, et al. Author Correction: Single-cellRNA-seq reveals that glioblastoma recapitu-lates a normal neurodevelopmental hierarchy [J]. Nat Com-mun, 2020, 11(1): 4041.
[7] Bazzoni R, Bentivegna A. Role of Notch signaling pathwayin glioblastoma multiforme pathogenesis [J]. Cancers, 2019,11(3): 292.
[8] Shevchenko V, Arnotskaya N, Korneyko M, et al. Proteins of the Wnt signaling pathway as targets for the regulation ofCD133+ cancer stem cells in glioblastoma [J]. Oncol Rep,2019, 41(5): 3080-3088.
[9] Bhuvanalakshmi G, Gamit N, Patil, et al. Stemness, pluripo-tentiality, and Wnt antagonism: sFRP4, a Wnt antagonistmediates pluripotency and stemness in glioblastoma [J].Cancers, 2018, 11(1): 25.
[10] Touat M, Li YY, Boynton AN, et al. Mechanisms and thera-peutic implications of hypermutation in gliomas [J]. Nature,2020, 580(7804): 517-523.
[11] Daniel P, Sabri S, Chaddad A, et al. Temozolomide induced hypermutationin glioma: evolutionary mechanisms andtherapeutic opportunities [J]. Front Oncol, 2019, 9: 41.
[12] Quick QA, Gewirtz DA. An accelerated senescence response to radiation in wild-type p53 glioblastomamultiforme cells [J]. J Neurosurg, 2006, 105(1): 111-118.
[13] McFarland CD, Yaglom JA, Wojtkowiak JW, et al. The damaging effect of passenger mutations on cancer progres-sion [J]. Cancer Res, 2017, 77(18): 4763-4772.
[14] Negi N, Das BK. CNS: Not an immunoprivilaged site any-more but a virtual secondary lymphoid organ [J]. Int RevImmunol, 2018, 37(1): 57-68.
[15] Goenka A, Tiek D, Song X, et al. The many facets of therapyresistance and tumor recurrence in glioblastoma [J]. Cells,2021, 10(3): 484.
[16] Zhang N, Wei L, Ye M, et al. Treatment progress of immunecheckpoint blockade therapy for glioblastoma [J]. FrontImmunol, 2020, 11: 592-612.
[17] Wang F, Wang S, Zhou Q. The resistance mechanisms oflung cancer immunotherapy [J]. Front Oncol, 2020, 10:568059.
[18] Darman RB, Seiler M, Agrawal AA, et al. Cancer-associated SF3B1 hotspot mutations induce Cryptic 3.0splice site selection through use of a different branch point[J]. Cell Rep, 2015, 13(5): 1033-1045.
[19] Correa BR, Araujo PR, Qiao M, et al. Functional genomicsanalyses of RNA-binding proteins reveal the splicingregulator SNRPB as an oncogenic candidate in glioblastoma[J]. Genome Biol, 2016, 17(1): 125.
[20] Margison GP, Koref MFS, Povey AC. Mechanisms of carci-nogenicity/chemotherapy by O6-methylguanine [J]. Muta-genesis, 2002, 17: 483-487.
[21] Pepponi R, Marra G, Fuggetta MP, et al. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repairactivities on the sensitivity of human melanoma cells totemozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, andcisplatin [J]. J Pharmacol Exp Ther, 2003, 304(2): 661-668.
[22] Chen PH, Shen WL, Shih CM, et al. The CHAC1-inhibited Notch3 pathway is involved in temozolomide inducedglioma cytotoxicity [J]. Neuropharmacology, 2017, 116:300-314.
[23] Zhang X, Yu J, Zhao C, et al. MiR-181b-5p modulates chemosensitivity ofglioma cells to temozolomide bytargeting Bcl-2 [J]. Biomed Pharmacother, 2019, 109:2192-2202.
[24] Zhang W, Zhang J, Hoadley K, et al. miR-181d: a predic-tive glioblastoma biomarker that downregulates MGMTexpression [J]. Neuro Oncol, 2012, 14(6): 712-719.
[25] Guo XR, Wu XY, Dai LJ, et al. Nuclear FAM289-Galectin-1 interaction controls FAM289-mediated tumor promotionin malignant glioma [J]. J Exp Clin Cancer Res, 2019, 38(1):394.
[26] Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFRkinase inhibitors [J]. N Engl J Med, 2005, 353(19): 2012-2024.
[27] Kant S, Kesarwani P, Guastella AR, et al. Perhexiline demonstrates FYN-mediated antitumor activity in glioblas-toma [J]. Mol Cancer Ther, 2020, 19(7): 1415-1422.
[28] Martin-Hijano L, Sainz BJ. The interactions between cancerstem cells and the innate interferon signaling pathway [J].Front Immunol, 2020, 11: 526.
[29] Martikainen M, Essand M. Virus-based immunotherapy ofglioblastoma [J]. Cancers, 2019, 11(2): 186.
[30] Fei X, Wang J, Chen C, et al. Eupatilin inhibits gliomaproliferation, migration, andinvasion by arresting cell cycleat G1/S phase and disrupting the cytoskeletal structure [J].Cancer Manag Res, 2019, 11: 4781-4796.
[31] Wu S, Zhou Y, Yang G, et al. Sulforaphane-cysteineinduces apoptosis by sustainedactivation of ERK1/2 andcaspase 3 in human glioblastoma U373MG and U87MGcells [J]. Oncol Rep, 2017, 37(5): 2829-2838.
相似文献/References:
[1]付 锴 江普查 宫 睿 王 伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(02):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳 琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫 珊 徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(02):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮 夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(02):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民 褚会松 田 甜 王昆鹏 杨国军 杨立军 王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(02):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述 王 辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰 姚庆和 李晓辉 龙宇波 陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(02):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘 靖 吴立权 黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(02):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘 炎 杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明 胡新华 刘 永 陈 玖 刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]
[11]胡峻龙 赵世光.替莫唑胺治疗脑胶质瘤的新进展[J].中国临床神经外科杂志,2021,26(08):647.[doi:10.13798/j.issn.1009-153X.2021.08.024]